Benefit of 5 years of enzyme replacement therapy in advanced late onset Pompe. A case report of misdiagnosis for three decades with acute respiratory failure at presentation
We report on a 57 year old female patient who presented in acute respiratory failure with severe generalized weakness. She was previously misdiagnosed for over three decades as polymyositis. She was treated with enzyme replacement therapy (ERT) for over five years, after being diagnosed with late on...
Main Authors: | Mandat Maharaj, David L. Skidmore, Sidney E. Croul, David J. Brake, Hanns Lochmuller |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-09-01
|
Series: | Molecular Genetics and Metabolism Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426922000568 |
Similar Items
-
Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
by: Priya S. Kishnani, et al.
Published: (2023-12-01) -
Late-onset Pompe disease - literature review and summary of current knowledge
by: Karolina Jaskuła, et al.
Published: (2023-01-01) -
Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa
by: Chris Carter, et al.
Published: (2024-01-01) -
Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy
by: Hui-An Chen, et al.
Published: (2024-04-01) -
A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
by: Barry J. Byrne, et al.
Published: (2017-08-01)